United States Food and Drug Administration (USFDA) has conducted an inspection at Caplin Point Laboratories’ Sterile Injectable Site (CP - IV) located at Gummudipoondi in the state of Tamil Nadu, from August 30, 2018 to September 06, 2018. This was a scheduled inspection and at the end of the inspection, there were ZERO 483s.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
